Citations

Showing 10 of 108119 citations.

Molecular breast imaging detected invasive lobular carcinoma in dense breasts: A case report
Samreen, Naziya , Hunt, Katie N. , Rhodes, Deborah J. , Hruska, Carrie B.

Mayo Clinic

Clinical Case Reports | January 28, 2019 | Volume: 7 | Issue: 3 | Pages: 442-444

10.1002/ccr3.1945 | PMID 30899468 Get It

Key Clinical Message This case highlights the role of molecular breast imaging (MBI) in evaluating persistent clinical concerns after a negative diagnostic mammogram and ultrasound. MBI is especially useful in the diagnosis of invasive lobular carcinoma due to its occult nature on conventional imaging modalities.
Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance)
Weiser, Martin R. , Mamon, Harvey J. , Gollub, Marc J. , Basch, Ethan , Shi, Qian , Shi, Qian , Gollub, Marc , Schrag, Deborah , Saltz, Leonard B. , Basch, Ethan , Venook, Alan P.

Mayo Clinic

Clinical Trials | January 28, 2019 | Volume: 16 | Issue: 2 | Pages: 165-175

10.1177/1740774518824539 | PMID 30688523 Get It

Background More than half of the 40,000 incident rectal cancer patients in the United States each year are diagnosed at clinical stage II and III (locally advanced stage). For this group, high rates of cure can be achieved with the combination of pelvic radiation and sensitizing 5-fluorouracil (chemoradiation), surgery and chemotherapy, but treatment is long, arduous and toxicities are substantial. The PROSPECT trial (N1048, NCT01515787) was designed to determine whether neoadjuvant chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX) could be used as an alternative to neoadjuvant chemoradiation without compromising treatment outcomes and to spare these patients excess toxicity. The statistical design balanced the twin co-primary goals of achieving low local and distant recurrence rates. Study design features contended with the need for stringent safeguards given limited phase II data, the need for straightforward criteria to facilitate both accrual and protocol fidelity and the importance of patients’ perspectives on symptom burden and treatment toxicity. Methods PROSPECT is an ongoing multi-site two-group seamless phase II/III randomized trial comparing standard neoadjuvant chemoradiation versus neoadjuvant chemotherapy with selective use of chemoradiation for patients with locally advanced rectal cancer. Challenges addressed in the design and conduct of PROSPECT have included the following: (1) setting safety thresholds given limited single-center phase II data, (2) establishing workable eligibility criteria, (3) balancing competing time to local and distant recurrence as co-primary endpoints and (4) obtaining reliable and complete data for patients’ symptom burden. The design and implementation challenges, choices, modifications and their implications for the design of future national cooperative group clinical trials are presented. Results PROSPECT incorporated stringent thresholds for both complete surgical resection (R0) and the time to local recurrence as early stopping rules. When predetermined stopping criteria were not met after evaluation of the first 366 participants in the randomized phase II, the study transitioned seamlessly to phase III with cumulative accrual of over 1000 participants. Eligibility criteria stipulating rectal tumor location based on distance from the anal verge were unworkable, and the protocol was amended to a more pragmatic approach that assigned surgeons with primary responsibility for determining eligibility. Central radiology review was feasible and in some cases prompted discontinuation of protocol treatment. Participation in toxicity reporting using the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events was uniformly high and was well accepted by participants from over 200 sites in the United States, Canada and Switzerland. Conclusion The strategies used to overcome these obstacles may inform the design of other studies that involve multi-modality treatment interventions, particularly trials where implementation of consistent criteria for eligibility and outcomes across hundreds of practice settings is necessary.
Caveolae, caveolin-1 and lung diseases of aging
Wicher, Sarah A. , Prakash, Y. S. , Prakash, Y S , Pabelick, Christina M.

Mayo Clinic

Expert Review of Respiratory Medicine | January 28, 2019 | Volume: 13 | Issue: 3 | Pages: 291-300

10.1080/17476348.2019.1575733 | PMID 30686114 Get It

Desmoplastic melanoma: a brief review and the efficacy of immunotherapy
Ochoa, Cesar E. , Joseph, Richard W.

Mayo Clinic

Expert Review of Anticancer Therapy | January 28, 2019 | Volume: 19 | Issue: 3 | Pages: 205-207

10.1080/14737140.2019.1574573 | PMID 30686076 Get It

Correction for Schmidt-Malan et al., “ In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli”
Schmidt-Malan, Suzannah M., Mishra, Avisya J., Mushtaq, Ammara , Brinkman, Cassandra L., Patel, Robin , Patel, Robin

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 28, 2019 | Volume: 63 | Issue: 2 | Pages: No page available

10.1128/aac.02563-18 | PMID 30696694 Get It

Left ventricular remodeling and function after transapical versus transfemoral transcatheter aortic valve replacement
Al‐Hijji, Mohammed , Zack, Chad, Pislaru, Sorin V. , Pellikka, Patricia A. , Reeder, Guy S., Greason, Kevin L. , Rihal, Charanjit S. , Eleid, Mackram F. , Al-Hijji, Mohammed A , Zack, Chad J, Eleid, Mackram F , Sabbah, Michael S. , Pellikka, Patricia A , Nkomo, Vuyisile T. , Rihal, Charanjit S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 28, 2019 | Volume: 94 | Issue: 5 | Pages: 738-744

10.1002/ccd.28074 | PMID 30688003 Get It

AbstractBackgroundThe effect of utilizing transapical (TA) access for transcatheter aortic valve replacement (TAVR) on cardiac function has not been well studied.AimsThe aim of this retrospective study is to determine the direct effects of TA access for TAVR on myocardial function parameters and their correlation with 4‐year survival.MethodsThree hundred and thirty propensity matched patients, who underwent TAVR using Sapien valve (Edwards Lifesciences Corp, Irvine, CA) between February 15, 2012 and June 17, 2016 (115 TA and 115 transfemoral [TF] routes) were studied. The pre‐ and 1 month post‐TAVR echocardiographic features of both groups were compared. The 4‐year survival in both groups was analyzed.ResultsBaseline clinical characteristics, diastolic function parameters, left ventricular (LV) chamber size, and ejection fraction were similar between matched TA and TF groups. At 1 month following TAVR, there was a significant increase in stroke volume index (SVI) in both TA (mean increase 7 cm3/m2; P = 0.03) and TF groups (mean increase 7 cm3/m2; P < 0.001). Left ventricular ejection fraction (LVEF) significantly increased post TF TAVR (mean increase 2%; P = 0.008), but no significant increase was observed post TA TAVR (mean increase 1%; P = 0.27). Both groups had significant improvement in aortic valve (AV) hemodynamics post‐TAVR (P < 0.001). Overall, there were no significant differences in the mean change of SVI, LVEF, or left ventricular end diastolic dimensions (LVEDDs) post TA versus TF TAVR. There was no significant difference in 4‐year survival in the TF compared to TA group (49% vs 50%, P = 0.43).ConclusionBoth TA and TF TAVR were equally associated with favorable changes in LV SVI and AV hemodynamics in 30 days. TA TAVR patients had similar 4 year survival to propensity matched TF TAVR; therefore, TA TAVR remains an acceptable alternative access route in patients not amenable to TF TAVR.
The use of motor learning and neural plasticity in rehabilitation for ataxic hemiparesis: A case report
Crum, Ellen O., Baltz, Mathew J., Krause, David A. , Crum, Ellen O.

Mayo Clinic

Physiotherapy Theory and Practice | January 27, 2019 | Volume: 36 | Issue: 11 | Pages: 1256-1265

10.1080/09593985.2019.1566941 | PMID 30686101 Get It

Early Results of a Phase I Trial Using an Adipose-Derived Mesenchymal Stem Cell-Coated Fistula Plug for the Treatment of Transsphincteric Cryptoglandular Fistulas
Dozois, Eric J. , Mathis, Kellie L. , Chua, Heidi K, Dietz, Allan B. , Friton, Jessica, Butler, Greg W., Faubion, William A. , Kelley, Scott R. , Friton, Jessica J, Dietz, Allan B , Lightner, Amy L. , Fletcher, Joel G.

Mayo Clinic

Diseases of the Colon & Rectum | January 26, 2019 | Volume: 62 | Issue: 5 | Pages: 615-622

10.1097/dcr.0000000000001333 | PMID 30664554 Get It

BACKGROUND: Management of transsphincteric cryptoglandular fistulas remains a challenging problem and the optimal surgical approach remains elusive. Mesenchymal stem cells, increasingly being utilized for perianal Crohn’s disease, offer a novel therapy to treat cryptoglandular fistulas. OBJECTIVES: This study aimed to determine safety and feasibility of using an autologous mesenchymal stem cell-coated fistula plug in patients with transsphincteric cryptoglandular fistulas. DESIGN: This study is a phase I clinical trial. SETTING: This study was conducted at a tertiary academic medical center. PATIENTS: Adult (>18 years) male and female patients with transsphincteric cryptoglandular fistulas were selected. MAIN OUTCOMES MEASURES: The primary outcomes measured were the safety, feasibility, and efficacy of a mesenchymal stem cell-coated fistula plug in patients with transsphincteric fistulas. RESULTS: Fifteen patients (8 women, mean age 39.8 years) with a single-tract transsphincteric fistula received a mesenchymal stem cell-loaded fistula plug and were followed for 6 months. Duration of disease at the time of study enrollment was a median of 3.0 years (range, 1–13 years) with a median of 3.5 (range, 1–20) prior surgical interventions. Adverse events included 1 plug extrusion, 1 abdominal wall seroma, 3 perianal abscesses requiring drainage, and 1 patient with perianal cellulitis. There were no serious adverse events. At 6 months, 3 patients had complete clinical healing, 8 had partial healing, and 4 patients showed no clinical improvement. Radiographic improvement was seen in 11 of 15 patients. LIMITATIONS: This study was limited by the small cohort and short follow-up. CONCLUSIONS: Autologous mesenchymal stem cell-coated fistula plug treatment of transsphincteric cryptoglandular fistulas was safe and feasible and resulted in complete or partial healing in a majority of patients. See Video Abstract at http://links.lww.com/DCR/A897.
Prevalence of Sporadic Vestibular Schwannoma: Reconciling Temporal Bone, Radiologic, and Population-based Studies
Marinelli, John P. , Lohse, Christine M. , Carlson, Matthew L. , Grossardt, Brandon R.

Mayo Clinic

Otology & Neurotology | January 26, 2019 | Volume: 40 | Issue: 3 | Pages: 384-390

10.1097/mao.0000000000002110 | PMID 30688755 Get It

Objective: Reported epidemiologic data surrounding vestibular schwannoma (VS) are controversial. Temporal bone prevalence studies have suggested that VS affects up to 2.4% of the population, whereas magnetic resonance imaging (MRI) studies have reported VS to affect 0.017%. Moreover, existing population-based data seem to underestimate the commonness of VS. In an attempt to reconcile temporal bone, radiologic, and population-based reports regarding VS, the current study was conceived to determine the modern prevalence of VS using a unique epidemiological database. Patients: All persons living in Olmsted County, Minnesota on January 1, 2017 with a confirmed diagnosis of sporadic VS identified using the Rochester Epidemiology Project (REP) medical records-linkage system. Main Outcome Measures: Prevalence of all VS and asymptomatic, incidentally diagnosed VS. Results: Sixty-seven persons from a population of nearly 160,000 were living with VS on January 1, 2017, resulting in a point prevalence of 42.0 per 100,000 persons. The prevalence increased with older age, reaching 212.4 per 100,000 in those ≥ 70 years. Including only persons who have undergone head MRI, the prevalence of asymptomatic, incidentally diagnosed VS was 69.9 per 100,000 among adults age 20 years and older. Conclusions: Using the unique infrastructure of the REP, the current study suggests that the clinical prevalence of sporadic VS approximates 1 in 2,000 adults and 1 in every 500 persons aged 70 years and older, with the prevalence of incidentally diagnosed tumors closely paralleling past MRI studies. These data characterize a shift in the modern patient demographic of sporadic VS, as now many people bearing a diagnosis of VS would have previously died without knowledge of their disease. Moreover, they typify an unfolding transition from an era of microsurgery and radiosurgery to the beginnings of an era that will be largely comprised of “chronic disease management.”